HemaCare Corporation  

(Public, OTCMKTS:HEMA)   Watch this stock  
Find more results for PINK:HEMA
0.000 (0.00%)
Jun 27 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range     -
52 week 0.11 - 0.45
Open     -
Vol / Avg. 0.00/11,181.00
Mkt cap 1.34M
P/E     -
Div/yield     -
EPS -0.07
Shares 10.33M
Beta -4.14
Inst. own 5%

Key stats and ratios

Q4 (Dec '12) 2012
Net profit margin -2.36% -4.23%
Operating margin -2.32% -4.10%
EBITD margin - -0.17%
Return on average assets -5.41% -9.08%
Return on average equity -7.83% -15.94%
Employees 85 -
CDP Score - -


Suite 350, 15350 Sherman Way
VAN NUYS, CA 91406
United States - Map
+1-877-3100717 (Phone)
+1-818-2515300 (Fax)

Website links


HemaCare Corp. (HemaCare) operates in two segments: blood products and therapeutic services. The blood products segment includes the sale of apheresis platelets on an exclusive basis to The American National Red Cross (ARC), and sales of other blood products to research, cellular therapy and other health and biotech related organizations. In the therapeutic services segment, the Company performs therapeutic apheresis procedures, stem cell collection, and other blood treatments on patients with a variety of disorders. Therapeutic services are provided under contract with hospitals as an outside purchased service. In October 2013, HemaCare Corp. completed the sale of its Coral Blood Services subsidiary to the New York Blood Center (NYBC).

Officers and directors

Steven B. Gerber M.D. Independent Chairman of the Board
Age: 57
Peter C. Van der Wal President, Chief Executive Officer,Director
Age: 55
Lisa Bacerra Chief Financial Officer
Age: 54
Anna Stock Chief Operating Officer
Age: 56
Teresa S. Sligh M.D. Independent Director
Age: 50
Julian L. Steffenhagen Independent Director
Age: 68
Terry Van Der Tuuk Independent Director
Age: 71